EPLONTERSEN SODIUM - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for eplontersen sodium and what is the scope of freedom to operate?
Eplontersen sodium
is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Eplontersen sodium has two hundred and twenty-eight patent family members in thirty-five countries.
One supplier is listed for this compound.
Summary for EPLONTERSEN SODIUM
| International Patents: | 228 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | EPLONTERSEN SODIUM at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for EPLONTERSEN SODIUM
Generic Entry Date for EPLONTERSEN SODIUM*:
Constraining patent/regulatory exclusivity:
TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for EPLONTERSEN SODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for EPLONTERSEN SODIUM
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 113293163 | 用于调节载脂蛋白C-III表达的组合物和方法 (COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION) | ⤷ Try a Trial |
| European Patent Office | 4155403 | COMPOSÉS ANTISENS CONJUGUÉS ET LEUR UTILISATION (CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE) | ⤷ Try a Trial |
| Brazil | 112015027377 | COMPOSTOS OLIGOMÉRICOS COM GRUPOS DE CONJUGADO, COMPOSIÇÕES COMPREENDENDO OS REFERIDOS COMPOSTOS E USOS DOS MESMOS | ⤷ Try a Trial |
| Brazil | 112015027369 | composições e métodos para modular a expressão de hbv e ttr | ⤷ Try a Trial |
| Israel | 284593 | הרכבים ושיטות למודולציה של ביטוי hbv ו- ttr (Compositions and methods for modulating hbv and ttr expression) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
